Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Tumor immune microenvironments may provide clues to future therapies, say UCSF-led researchers.
The median progression- free survival time was 6.5 months, and the median overall survival time was 12.6 months.
Chronic inflammation can promote tumor growth, and controlling it could help fight cancer.
Every year, 350 children in the United States are diagnosed with rhabdomyosarcoma.
A micro-organosphere model of an individual patient’s cancer may help advance precision oncology.
The combination of target drugs Tafinlar-Mekinist is approved for nearly any type of advanced solid tumor that has the BRAF gene mutation.
A gene called FOXR2 that is normally turned off is activated in at least 70% of cancer types. Can it be targeted with new treatments?
Most pancreatic cancer cells have relatively few mutations on their surface to attract the attention of cancer-killing immune T cells.
Understanding the evolutionary path that tumors follow is essential for designing effective clinical interventions.
Researchers are developing new treatments for people with HER2-positive breast cancer.
Genomic tumor profiling in pediatric patients can clarify diagnosis and treatment, a recent study found.
Artificial intelligence and machine learning can help identify genetic changes that lead to cancer—and which treatments work best.
Around 20% to 30% of meningiomas are aggressive and potentially deadly.
Allergy meds were linked to longer survival among cancer patients treated with immune checkpoint inhibitors.
Discovery in head and neck cancers may open door for targeted immune-boosting drugs
People who received the combination lived longer without experiencing serious events, including their cancer returning.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.